Irlanda - inglés - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

accord healthcare limited - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Canadá - inglés - Health Canada

omega laboratories limited - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

Estados Unidos - inglés - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml

Estados Unidos - inglés - NLM (National Library of Medicine)

mylan institutional llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Estados Unidos - inglés - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin injection and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existi

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisplatin 10 mg/10 ml - concentrate for solution for infusion - 1 mg/ml - cisplatin 1 mg/ml - cisplatin